Odenthal Johanna, Dittrich Sebastian, Ludwig Vivian, Merz Tim, Reitmeier Katrin, Reusch Björn, Höhne Martin, Cosgun Zülfü C, Hohenadel Maximilian, Putnik Jovana, Göbel Heike, Rinschen Markus M, Altmüller Janine, Koehler Sybille, Schermer Bernhard, Benzing Thomas, Beck Bodo B, Brinkkötter Paul T, Habbig Sandra, Bartram Malte P
Department II of Internal Medicine and Center for Molecular Medicine Cologne, Faculty of Medicine, University of Cologne, University Hospital Cologne, Cologne, Germany.
Center for Molecular Medicine Cologne, Faculty of Medicine, University of Cologne, University Hospital Cologne, Cologne, Germany.
Kidney Int Rep. 2022 Oct 31;8(2):317-329. doi: 10.1016/j.ekir.2022.10.024. eCollection 2023 Feb.
Genetic disorders are among the most prevalent causes leading to progressive glomerular disease and, ultimately, end-stage renal disease (ESRD) in children and adolescents. Identification of underlying genetic causes is indispensable for targeted treatment strategies and counseling of affected patients and their families.
Here, we report on a boy who presented at 4 years of age with proteinuria and biopsy-proven focal segmental glomerulosclerosis (FSGS) that was temporarily responsive to treatment with ciclosporin A. Molecular genetic testing identified a novel mutation in alpha-actinin-4 (p.M240T). We describe a feasible and efficient experimental approach to test its pathogenicity by combining , , and analyses.
The p.M240T mutation led to decreased alpha-actinin-4 stability as well as protein mislocalization and actin cytoskeleton rearrangements. Transgenic expression of wild-type human alpha-actinin-4 in nephrocytes was able to ameliorate phenotypes associated with the knockdown of endogenous actinin. In contrast, p.M240T, as well as other established disease variants p.W59R and p.K255E, failed to rescue these phenotypes, underlining the pathogenicity of the novel alpha-actinin-4 variant.
Our data highlight that the newly identified alpha-actinin-4 mutation indeed encodes for a disease-causing variant of the protein and promote the model as a simple and convenient tool to study monogenic kidney disease .
遗传性疾病是导致儿童和青少年进行性肾小球疾病并最终发展为终末期肾病(ESRD)的最常见原因之一。确定潜在的遗传原因对于制定针对性的治疗策略以及为受影响的患者及其家庭提供咨询至关重要。
在此,我们报告一名4岁男孩,他出现蛋白尿,经活检证实为局灶节段性肾小球硬化(FSGS),对环孢素A治疗有暂时反应。分子基因检测在α-辅肌动蛋白-4中发现了一个新的突变(p.M240T)。我们描述了一种可行且高效的实验方法,通过结合[此处原文缺失相关分析方法名称]分析来测试其致病性。
p.M240T突变导致α-辅肌动蛋白-4稳定性降低以及蛋白质定位错误和肌动蛋白细胞骨架重排。在[此处原文缺失相关细胞名称]肾细胞中野生型人α-辅肌动蛋白-4的转基因表达能够改善与内源性辅肌动蛋白敲低相关的表型。相比之下,p.M240T以及其他已确定的疾病变体p.W59R和p.K255E未能挽救这些表型,突出了新的α-辅肌动蛋白-4变体的致病性。
我们的数据表明,新鉴定的α-辅肌动蛋白-4突变确实编码该蛋白的致病变体,并将[此处原文缺失相关模型名称]模型推广为研究单基因肾病的简单便捷工具。